retatrutide benefits clinical trial Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a retatrutide type 2 diabetes phase

Novel Modalities OrsoBio is advancing a novel approach to obesity treatment to address hallmarks of metabolic dysfunction where GLP-1s alone may not fully cover

Potential Cardiovascular Benefits: Some patients experience lower cholesterol and blood pressure as their body weight and metabolic health improve

There is no magic pill or injection that will change your metabolism or your habits

These results highlight the mechanisms by which G6PD dysregulation may contribute to cancer or autoimmune diseases

Cardiovascular outcome studies in type 2 diabetes: comparison between SGLT2 inhibitors and GLP-1 receptor agonists